Browse the evidence

Baseline gut microbiome composition predicts the efficacy of semaglutide and empagliflozin in reducing HbA1c, whereas the drugs themselves do not significantly alter microbial diversity or composition.

If you are starting semaglutide or empagliflozin for Type 2 Diabetes, your current gut bacteria might predict how much your blood sugar (HbA1c) will drop. The drugs themselves don't seem to drastically change your gut diversity, but knowing your baseline microbiome could help personalize your treatment. This is still early research, so discuss testing options with your doctor.

Pharmacotherapy may reduce bariatric surgical volume, particularly among patients with BMI 30-40, by providing a less invasive alternative.

If you have a BMI between 30 and 40, you now have a highly effective non-surgical option that may prevent the need for surgery. This is changing how doctors treat obesity.

Phentermine is generally avoided in older adults due to risks of falls, anxiety exacerbation, and cardiovascular side effects, despite its efficacy in younger populations.

Phentermine is rarely recommended for older adults because it can cause dizziness (increasing fall risk), worsen anxiety, and strain the heart. It is generally avoided in this age group due to multiple comorbidities.

Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.

If you start Tirzepatide, expect gastrointestinal issues like nausea or diarrhea, especially in the first month. These are common reasons for stopping treatment. Starting at the lowest dose (5mg) might help you tolerate the medication better, as higher doses are linked to later but potentially more severe onset of side effects. Monitor your symptoms closely during the first few weeks.

Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.

If you are over 65 and start Tirzepatide, be extra vigilant in the first two weeks. Side effects like nausea or dizziness may hit you much sooner than they would for a younger person. Report any severe symptoms to your doctor immediately, as discontinuation rates are higher in this age group.

GLP-1 receptor agonist use is associated with an increased risk of hair loss (alopecia, telogen effluvium), with incidence potentially correlated with the magnitude of weight loss.

If you are using a GLP-1 agonist (like Ozempic or Mounjaro) and notice increased shedding or thinning, this is a known potential side effect, often linked to rapid weight loss or hormonal shifts. It does not happen to everyone, and in some cases, hair regrowth has been observed. Do not stop your medication abruptly without consulting your doctor; discuss monitoring strategies or temporary pauses if the hair loss is severe.

Therapeutic inhibition of myostatin using inhibitors or antibodies is a potential treatment for muscle-wasting disorders like Duchenne muscular dystrophy, sarcopenia, and cachexia, but long-term safety and functional integrity are concerns.

Myostatin inhibitors are experimental treatments for serious muscle-wasting diseases. They are not available or recommended for healthy individuals. If you have a wasting disorder, consult a specialist about clinical trials. Do not attempt to self-administer myostatin blockers.

Personalized nutrition does not significantly reduce fasting blood glucose compared to control diets in adults with prediabetes or type 2 diabetes.

While personalized nutrition improves HbA1c and postprandial responses, it may not significantly lower fasting blood glucose compared to standard diets in the short term. Patients should focus on overall glycemic control (HbA1c) rather than just fasting numbers.

Tilorone attenuates high-fat diet-induced hepatic steatosis and improves glucose tolerance in mice by enhancing BMP9-Smad1/5/8 signaling and upregulating PPARγ expression.

This preclinical study suggests that tilorone, administered via intraperitoneal injection, can reduce liver fat and improve glucose metabolism in mice on a high-fat diet by activating specific signaling pathways. However, as this is an animal study using a synthetic small molecule administered via injection, it does not currently provide a direct, actionable protocol for human dietary or lifestyle intervention. Clinical trials are required to determine efficacy and safety in humans.

Liraglutide is associated with higher rates of anxiety and medication switching compared to Tirzepatide and Semaglutide.

If you have a history of anxiety, Liraglutide might not be the best choice, as this study found it was associated with higher anxiety rates and more medication switches compared to Tirzepatide and Semaglutide. Tirzepatide may offer a better balance of efficacy and tolerability for you.

GLP-1 receptor agonists are associated with reduced risks of various psychiatric disorders, including substance use disorders, suicidal ideation, and dementia, suggesting potential neuroprotective benefits beyond weight management.

While GLP-1RAs are primarily used for weight loss, emerging large-scale data suggests they may also reduce the risk of certain psychiatric conditions like dementia and substance use disorders. However, these benefits are observational, and more research is needed to confirm if GLP-1RAs directly cause these improvements or if other factors are involved.

The association between GLP-1 RAs and reduced cancer risk is not uniform across the class; liraglutide and semaglutide show reduced risk, while dulaglutide shows a neutral association.

While the class as a whole does not increase cancer risk, the protective effect may vary by drug. Liraglutide and semaglutide show signals of reduced risk, whereas dulaglutide shows a neutral effect. This suggests that the choice of GLP-1 RA might matter for long-term oncological safety, though more research is needed.

GLP-1 receptor agonists (GLP-1RAs) used for weight management and obesity are associated with a significantly higher risk of psychiatric adverse events, including suicidal behavior, panic attacks, and depressive disorders, compared to their use in diabetes treatment.

If you are using a GLP-1 medication (like semaglutide or tirzepatide) for weight loss, be aware that reports of mood changes, including anxiety, panic, or suicidal thoughts, are higher in weight management users than in diabetes users. Discuss these risks with your doctor before starting. If you experience sudden mood changes, contact your provider immediately. This does not mean everyone will experience this, but it is a known signal to monitor.

GLP-1 receptor agonists show potential therapeutic benefits for psychiatric conditions, including depression, anxiety, binge-eating disorder, and substance use disorders, though evidence quality varies.

GLP-1 agonists may help with depression, anxiety, and binge-eating disorder, in addition to weight loss. However, results for addiction (like alcohol) are mixed. Consult a psychiatrist or physician to see if these medications might support your mental health treatment, especially if you have obesity or diabetes.

Targeting the glucagon receptor (GCGR) with antagonists can promote beta-cell regeneration and improve beta-cell identity in Type 2 Diabetes models.

Research suggests that blocking the glucagon receptor (GCGR) might help regenerate insulin-producing beta cells in people with Type 2 Diabetes. This is a newer area of treatment development, moving beyond just replacing insulin to trying to repair the pancreas itself. While promising in animal studies, this is not yet a standard clinical practice for all patients.

Tirzepatide therapy significantly improves cardiac function (LVEF) and reduces cardiac stress (NT-proBNP) in patients with heart failure over a six-month period.

If you have heart failure and are prescribed tirzepatide, expect measurable improvements in your heart's pumping ability (LVEF) and reduced stress on your heart (NT-proBNP) within six months. This medication also improves your ability to walk and your overall quality of life. Ensure you are monitored by your healthcare provider for dosage adjustments and side effects.

Tirzepatide therapy significantly improves functional capacity (6MWT distance) and quality of life (KCCQ scores) in patients with heart failure.

If you have heart failure and are prescribed tirzepatide, you may experience an increased ability to walk and an overall improvement in your quality of life within six months. This means you might feel less short of breath and more capable of performing daily activities. Discuss these potential benefits with your healthcare provider.

Dysbiosis (specifically reduced SCFA-producing bacteria and increased pro-inflammatory taxa) contributes to the pathogenesis of Type 2 Diabetes through mechanisms involving gut permeability, LPS-driven inflammation, and impaired insulin signaling.

Maintaining gut health through a fiber-rich diet may help manage blood sugar levels by reducing inflammation and improving insulin sensitivity. This is particularly relevant for those with or at risk for Type 2 Diabetes.

Training to failure does not produce a repeated bout effect (RBE) that mitigates longitudinal fatigue or recovery differences over an 8-week period.

Training to failure does not seem to 'protect' you from future fatigue or soreness over time. If you choose to train to failure, expect similar fatigue levels to submaximal training in the long run, but potentially lower strength gains.

Social Determinants of Health (SDoH), including socioeconomic status, neighborhood environment, and food access, are strongly associated with obesity prevalence and weight regain, independent of individual clinical factors.

Your environment matters. If you live in an area with limited access to healthy food or safe places to exercise, maintaining weight loss is significantly harder. Recognizing these external barriers can help you seek community resources or advocate for policy changes that support your health goals.

Intentional weight loss induces physiological adaptations in energy expenditure and intake that actively oppose weight maintenance, contributing to weight regain.

If you have lost weight, expect your body to fight to regain it through increased hunger and lower energy burn. This is a biological adaptation, not a character flaw. Successful maintenance likely requires strategies that address these specific physiological drivers, such as managing hunger cues and adjusting activity levels, rather than relying on willpower alone.

Gastric greater curvature plication combined with Nissen fundoplication (GGCP + Nissen) produces significantly less long-term weight loss and inferior glucose homeostasis compared to sleeve gastrectomy (SG) in patients with obesity and type 2 diabetes models, despite being effective for GERD resolution.

If you have obesity and significant acid reflux, standard sleeve gastrectomy might worsen your reflux. A combined procedure (plication + Nissen) can fix your reflux and provide moderate weight loss, but it is less effective for weight loss and blood sugar control than standard sleeve gastrectomy. Choose based on whether reflux control or maximum weight loss is your primary goal.

Self-managed lifestyle interventions (diet and exercise) are the primary initial weight loss strategy in China, but they result in low compliance and modest efficacy, leading to a high unmet need for anti-obesity medications (AOMs).

If you are in China and trying to lose weight, know that self-managed diet and exercise are the standard first steps, but they often fail due to low compliance. If lifestyle changes aren't working, it is not your fault; the current options have limitations. Discuss anti-obesity medications (AOMs) with your doctor, as new options are becoming available and are desired by both patients and physicians for better efficacy and safety.

Anti-obesity medications (AOMs) are underutilized in China due to limited approved options and physician preference for lifestyle interventions, despite high patient willingness to try new AOMs.

If you are a physician in China, be aware that AOMs are underutilized due to limited options and safety concerns. However, patients are willing to try new AOMs. As new AOMs become available, consider prescribing them for patients who fail lifestyle interventions.